ERBB2 and breast carcinoma: Therefore, non-invasive imaging modalities using diagnostic tracers targeting HER2 could prove to be essential in patient selection and monitoring of disease progression, considering 25% of patients with HER2pos breast cancer will eventually develop brain metastases [25].